A polypill containing three recommended heart failure therapies improved heart function, reduced hospitalizations and was ...

Among patients with heart failure and reduced ejection fraction (HFrEF), those taking a "polypill" combination of three ...

A once-daily polypill containing 3 guideline-directed therapies for heart failure with reduced ejection fraction (HFrEF) led ...

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for ...

Ryan Haumschild, PharmD, MS, MBA: Dr Anderson, I’d like to start with you. We’ve talked about guideline recommendations. Can you briefly discuss some of the real-world differences in the treatment ...

Credit: Getty Images. The NDA is supported by data from the phase 3 GALACTIC-HF trial which included 8256 adults with heart failure with reduced ejection fraction, The Food and Drug Administration ...

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, ...

- In this clinical first for adults with heart failure with preserved ejection fraction, empagliflozin demonstrated an impressive 21 percent relative risk reduction in the composite primary endpoint ...

Please provide your email address to receive an email when new articles are posted on . Among patients undergoing high-risk PCI with mechanical circulatory support who survived to 90 days without ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

In this prospective, multicenter clinical trial, we randomly assigned patients with symptomatic, drug-resistant atrial fibrillation, an ejection fraction of 40% or less, and New York Heart Association ...